Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What Future For Genentech's Lebrikizumab On Phase III Failure?

This article was originally published in Scrip

Executive Summary

Roche/Genentech's IL-13 inhibiting investigational severe asthma product lebrikizumab has failed in one of its two pivotal trials, adding to reservations about its future. Lebrikizumab is already trailing other biological competitors to the market and the lack of robust data at Phase III could well spell the end in this indication.

You may also be interested in...



Almirall Extends Dermatology Reach With Dermira Lebrikizumab Deal

Almirall has re-affirmed its dermatology emphasis by entering a lebrikizumab option and license pact with Dermira for treating eczema in Europe.

Asthma Pipeline Pressure For AstraZeneca As STRATOS 1 Fails

The failure of AstraZeneca's novel asthma therapy in its first pivotal trial is of little surprise but increases the pressure on its other late-stage asthma product in this key therapy area for the company.

Teva Gets EU Green Light For Reslizumab

Teva is set to get its severe asthma treatment Cinqaero onto the EU market following a positive opinion from the CHMP but, as in the US, its label will restrict its use to adult patients.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC064628

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel